Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
11.04
+0.14 (1.28%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Crescent Biopharma Employees
Crescent Biopharma had 44 employees as of December 31, 2025. The number of employees increased by 38 or 633.33% compared to the previous year.
Employees
44
Change
38
Growth
633.33%
Revenue / Employee
$246,455
Profits / Employee
-$3,498,682
Market Cap
304.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 44 | - | - |
| Sep 30, 2025 | 41 | - | - |
| Jun 30, 2025 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 305 |
| AC Immune | 172 |
| Cabaletta Bio | 151 |
| Neurogene | 107 |
| Foghorn Therapeutics | 106 |
| Armata Pharmaceuticals | 60 |
| NovaBridge Biosciences | 32 |
| Climb Bio | 29 |
CBIO News
- 17 days ago - Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewsWire
- 25 days ago - Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Crescent Biopharma to Present at March Investor Conferences - GlobeNewsWire
- 4 weeks ago - Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors - GlobeNewsWire
- 6 weeks ago - Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors - GlobeNewsWire
- 3 months ago - Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors - GlobeNewsWire
- 3 months ago - Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics - GlobeNewsWire